- New sub-analysis on Trogarzo clinical trial patients demonstrates that long-term viral suppression is not influenced by partially active agents.
- Predictive pharmacokinetic modelling shows that new methods of administration could provide similar kinetics to intravenous infusion.
- Additional data highlights synergistic activities between Trogarzo and dolutegravir, etravirine, tenofovir alafenamide and lenacapavir, a long-acting investigational antiretroviral therapy (ARV).
Brazil’s Porter Airlines Places Order For Embraer’s E195-E2 Passenger Jets Worth $2.1B
Brazil-based Porter Airlines has exercised purchase rights to place a firm order for 25 Embraer SA (NYSE: ERJ) E195-E2 passenger jets.
